Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genedrive ( (GB:GDR) ) has issued an announcement.
Genedrive plc, a UK-based specialist in point-of-care pharmacogenetic testing for emergency and personalised medicine, has built a product suite around its Genedrive MT-RNR1 ID Kit for rapid antibiotic decision-making in neonatal intensive care and its CYP2C19 ID Kit for guiding antiplatelet choice in stroke patients, both backed by UK NICE recommendations and designed for rapid, on-site use without cold-chain logistics as part of a broader growth strategy in domestic and international healthcare markets. At its latest Annual General Meeting, all resolutions proposed to shareholders were duly passed with strong, though not unanimous, support across the proxy votes, reinforcing the company’s governance agenda and providing a mandate for management to continue executing its commercial and strategic plans in the pharmacogenetic testing space.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercialises low-cost, rapid point-of-care genetic tests to guide personalised medicine, with a particular focus on time-critical emergency healthcare. Its flagship products, the Genedrive MT-RNR1 ID Kit and CYP2C19 ID Kit, enable clinicians to quickly determine safe and effective use of antibiotics in neonatal intensive care and antiplatelet therapy in stroke patients, respectively, and are deployed on the company’s proprietary point-of-care thermocycler platform. Both single-use, ambient temperature-stable tests have been recommended for use in the UK NHS following review by NICE, supporting Genedrive’s strategy to grow through in-market sales, geographic expansion, portfolio development and strategic M&A from its Manchester base.
Average Trading Volume: 42,587,926
Technical Sentiment Signal: Strong Sell
Current Market Cap: £8.49M
For an in-depth examination of GDR stock, go to TipRanks’ Overview page.